(firstQuint)Study Evaluating Intepirdine (RVT-101) on Gait and Balance in Subjects With Dementia.

 To assess the effect of intepirdine (RVT-101) versus placebo on quantitative and qualitative gait and balance parameters.

 Each subject will be randomized 1:1 to one of the following sequences: Sequence 1: AB = RVT-101 35 mg during the early treatment period and Placebo during the late treatment period Sequence 2: BA = Placebo during the early treatment period and RVT-101 35 mg during the late treatment period Treatment A = RVT-101 35 mg once daily.

 Treatment B = Placebo once daily.

.

 Study Evaluating Intepirdine (RVT-101) on Gait and Balance in Subjects With Dementia@highlight

This study seeks to evaluate the effect of intepirdine (RVT-101) on gait and balance in patients with Alzheimer's Disease, Dementia with Lewy Bodies or Parkinson's Disease Dementia.

